Segment Information

12 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Information

NOTE 17: — SEGMENT INFORMATION

a.Geographic Area Information:

The Group operates in one industry segment, which produces, researches, develops, and markets pharmaceutical products. Management organizes the Company’s operations based on geographic segments, which are presented below in accordance with FASB ASC Paragraph 280-10-50-1, “Segment Reporting – Overall – Disclosure – Operating Segments.”

	Israel		Canada		U.S.A.		Other		Consolidated
Year ended March 31, 2022 and as of
March 31, 2022:
Net sales *	$	47,915	$	130,066	$	376,677	$	6,689	$	561,347
Long-lived assets **	$	117,913	$	101,387	$	31,191	$	8,355	$	258,846
Year ended March 31, 2021 and as of
March 31, 2021:
Net sales *	$	46,574	$	110,167	$	383,829	$	8,400	$	548,970
Long-lived assets **	$	122,983	$	61,027	$	35,455	$	—	$	219,465
Year ended March 31, 2020 and as of
March 31, 2020:
Net sales *	$	42,817	$	97,997	$	495,673	$	8,282	$	644,769
Long-lived assets **	$	123,679	$	63,506	$	38,379	$	—	$	225,564

* Based on customer’s location, including sales to unaffiliated customers and Sun.

** Includes property, plant and equipment, net; goodwill and intangible assets, net.

b.For the year ended March 31, 2022, the Company had net sales to two different U.S. customers of 10.1% and 8.9% of consolidated net sales. For the year ended March 31, 2021, the Company had net sales to two different U.S. customers of 12.6% and 10.5% of consolidated net sales. For the year ended March 31, 2020, the Company had net sales to two different U.S. customers of 13.0% and 11.5% of consolidated net sales.

c.Sales by therapeutic category, as a percentage of total net sales for the years ended March 31, 2022, 2021, and 2020, were as follows:

	Year ended March 31,
Category	2022			2021			2020
Dermatological and topical		60	%		58	%		63	%
Neuropsychiatric		13	%		16	%		17	%
Cardiovascular		6	%		7	%		6	%
Anti-inflammatory		3	%		3	%		3	%
Other		18	%		16	%		11	%
Total		100	%		100	%		100	%